Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON)
Build our future together: At Regeneron, we use science and innovation to develop life-changing medicines for people with serious diseases. We are seeking an Associate Director, Global Patient Advocacy, Hematology-Oncology to cover International and US markets. In
Our Mission At Circus (Xetra: CA1), headquartered in Munich, we are pioneering global developments in on-demand autonomous food production. Everything from creation to production and operation – enabled by seamlessly integrated cutting-edge robotics and transformative AI